Cerecor Inc (CERC) Share Price

New board is: https://investorshub.advfn.com/Avalo-Therapeutics-AVTX-40053/

$cerc Cerecor wins Fast Track Designation https://www.biospace.com/article/2021-covid-19-news-india-variant-a-global-concern-low-risk-of-serious-long-term-effects-and-more/

And up 25% this morning

Biggest negative operating margin ever seen -706.02%, book value $0.30 prob even less after earnings, some of the biggest negative returns see as well. Negative -$40+ million operating cash flow is real bad.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -706.02%

Management Effectiveness
Return on Assets (ttm) -74.02%
Return on Equity (ttm) -282.65%

Income Statement
Revenue (ttm) 6.7M
Revenue Per Share (ttm) 0.09
Gross Profit (ttm) -18.54M
EBITDA -45.45M
Net Income Avi to Common (ttm) -64.38M

Balance Sheet
Total Cash (mrq) 18.92M
Total Cash Per Share (mrq) 0.2
Total Debt (mrq) 1.46M
Total Debt/Equity (mrq) 5.96
Current Ratio (mrq) 1.71
Book Value Per Share (mrq) 0.30

Cash Flow Statement
Operating Cash Flow (ttm) -40.54M
Levered Free Cash Flow (ttm) -11.15M

https://www.marketwatch.com/story/cerecors-investigational-covid-19-therapy-gets-fast-track-designation-from-the-fda-2021-05-11

Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002

“Oppenheimer Weighs in on Cerecor Inc.’s FY2025 Earnings (NASDAQ:CERC)”

Read Here

Hanging strong in a volatile Daq market. Lots of news on their pipeline coming.

Good Luck!

Nice move in the overall market rally. Needs to go up above that 50dma and make it support. We’re close.

Just a heads up that CERC filed a $150 mil shelf registration yesterday. 2021 is a pivotal year for this company so I’m not surprised by it but it’s worth noting.

Good Luck!

Same

Added at 3.04 on the dip.

Good Luck!

Starter position on this dip under $3

Let’s gooooo

$2.60 in

Bought a lot of shares. Ready for a bull run soonish.

Interesting

COVID related update. Fundamentals are Excellent ... https://finance.yahoo.com/news/cerecor-announces-first-patient-enrolled-110010883.html

MASSIVE Insider Buying over past week !!


Transaction Date Insider Name Title Buy/Sell Number of Shares Average Share Price Total Transaction Shares Held After

Transaction Details
6/11/2020 Armistice Capital Master Fund Major Shareholder Buy 2,049,486 $2.44 $5,000,745.84

6/11/2020 Armistice Capital, Llc Director Buy 28,000 $2.44 $68,320.00

6/10/2020 Christopher Ryan Sullivan CFO Buy 2,954 $2.28 $6,735.12 2,954

6/9/2020 Armistice Capital, Llc Director Buy 1,753,680 $2.50 $4,384,200.00

6/9/2020 James Archie Harrell Jr Insider Buy 10,000 $2.50 $25,000.00 21,618

6/9/2020 Michael F Cola CEO Buy 100,000 $2.50 $250,000.00 175,746

News out today read here: Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study
DOWNLOAD AS PDFMAY 26, 2020
- Patients hospitalized with COVID-19 had significantly elevated levels of the inflammatory cytokine LIGHT

- LIGHT was strongly linked with mortality (82%) in patients over 60 years of age

- Decreasing LIGHT levels using CERC-002 (anti-LIGHT mAb) may prevent cytokine storm induced severe ARDS and thereby reduce mortality and the need for ventilation

ROCKVILLE, Md., May 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC) and Myriad Genetics Inc. (NASDAQ: MYGN) today announced that levels of novel cytokine, LIGHT, were highly correlated with disease severity and mortality in a COVID-19 acute respiratory distress syndrome (ARDS) biomarker study. The biomarker study was conducted using the serum samples of 47 hospitalized COVID-19 patients and 30 healthy controls from Hackensack Meridian Health Network.

In April 2020, approximately 1,500 people in the United States died each day from COVID-19. The viral infection triggers a hyperactive immune response leading to cytokine storm and Acute Respiratory Distress Syndrome (ARDS), which is a leading cause of death in patients who die of COVID-19. Although this hyperinflammatory process is poorly understood, the data from this study implicates the inflammatory cytokine, LIGHT, as a potential key driver of cytokine storm leading to ARDS and death.

LIGHT levels were significantly elevated in the serum of hospitalized patients with COVID-19 versus healthy controls (p value < 0.0001). The highest LIGHT levels were found in patients who required ventilator support, particularly in patients over 60. Importantly, the data demonstrated elevated LIGHT levels were also strongly linked with mortality (p=0.02).

Dr. David Perlin, Ph.D., chief scientific officer, senior vice president of the Center for Discovery and Innovation, and Professor of Medical Sciences at the Hackensack Meridian School of Medicine at Seton Hall University, commented “These data are compelling and demonstrate that the inflammatory cytokine LIGHT may play a key role in cytokine storm associated with COVID-19 ARDS that leads to increased morbidity and mortality. Reducing LIGHT levels might be a key to dampening the cytokine storm in these patients, preventing the need for ventilator support and reducing mortality.”

Dr. Garry Neil, M.D. chief scientific officer, Cerecor commented, “As a company, we recognized the impact of cytokine storm-induced ARDS and the need for treatment options for patients in this area of high unmet need. We remain focused on the CERC-002 clinical program and rapidly moving it forward for the treatment of cytokine storm induced ARDS.”

Role of LIGHT in Acute Inflammatory Response

LIGHT (homologous to Lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes) is a cytokine with inflammatory actions encoded by the TNFSF14 gene. LIGHT has been shown to play a key role in the immune response to viral pneumonia. LIGHT plays an important role in regulating immune responses in the lung, gut and skin. It stimulates T Cell and B Cell response as well as induces the release of other cytokines such as IL1, IL6, IL-8, IL-10, TNF and GM-CSF.

CERC-002 (anti-LIGHT monoclonal antibody)

CERC-002 is a fully human monoclonal antibody with neutralizing action against LIGHT (TNFSF14), for treatment of children with Pediatric Crohn’s Disease. Cerecor holds an open IND with FDA and the drug is currently being studied in a Phase I clinical trial for patients with refractory severe Crohn’s disease, currently not recruiting due to COVID-19

looks like they acquired product lines and not the company itself

according to the SEC doc. AYTU acquired CERC

https://www.sec.gov/Archives/edgar/data/1385818/000165495419013534/aytu_425.htm


Message in reply to:

Gnmx aquired by Cerc

Yeah. I used to have this under a dollar. Bought back in yesterday. Accumulation line looks real proper.

Looks like this stock took a beating after the acquisition if GNMX which I wasa shareholder of...

Gnmx aquired by Cerc!! on our way up!!! glta :)

$7-$8 coming

This company is going to be exciting soon will be keeping watch on this one

News: $CERC Cerecor Reports Second Quarter 2019 Results

-Positive Final Results with CERC-301 in nOH -First Patient Enrolled in CDG FIRST Trial - FDA Acceptance of IND Application of CERC-802 ROCKVILLE, Md., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development an...

Read the whole news Cerecor Reports Second Quarter 2019 Results

News: $CERC Cerecor Announces Positive Final Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (OH)

ROCKVILLE, Md., July 01, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced positive results from its comp...

Find out more https://marketwirenews.com/news-releases/cerecor-announces-positive-final-results-of-cerc-301-in-the-tre-8438912.html

News: $CERC Cerecor Added to Russell 3000® Index

ROCKVILLE, Md., June 28, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced that it has been added to the ...

Read the whole news https://marketwirenews.com/news-releases/cerecor-added-to-russell-3000-xae-index-8429182.html

News: $CERC Cerecor Set to Join Russell 3000® Index

ROCKVILLE, Md., June 11, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced that it is set to join the Rus...

In case you are interested https://marketwirenews.com/news-releases/cerecor-set-to-join-russell-3000-xae-index-8339290.html

Anybody out there following this growing company? Management moves awesome. Follow Boyd/Armistice and the path to success!!! Freed.

Beast

CERC buy 4.93

hammer candlestick at moving average support
bullish engulfing pattern
uptrending great and about to breakout over major resistance
chart really shows how the inverted head and shoulders bottom causes an uptrend that can last months and years
ascending triangle breakout with pullback
at a support level for a low risk high reward trade



https://www.cerecor.com/



















normal chart




log chart

CERC about to Break 52 week high

Bullish triangle breakout on 15-Feb-2018

Whatever is happening to this market, I'm glad it is not affecting Cerecor inc. The stock is holding up very well in this rough market. The DOW and NASDAQ took a beating yesterday. I thought Friday was bad, but it was nothing like yesterday, when the DOW was down nearly 1200 point. That was nerve wrecking.

Hedge funds loading.

Weeee

Running nice

$2.7 . bouncer . CERC

Happy New Year to all of Cerecor Inc shareholders and investors.

Back from the Christmas Holidays. Back in at $2.70, let's get going CERC.

Market maker magic from 4,10 to 3,80's with like noch Volume lol

Wooowzaaaaa

New 52 week high

Go CERC

true monster $$$$$$ . CERC

axelvento grazie che hai postato mesi fa su CERC, tu hai promosso il tuo diritto grazie! Tutto il meglio per te 2018

2018 going be huge not worth flipping